The HBV capsid core protein serves a number of important functions in the viral life cycle enabling chronic HBV infection to persist, and therefore is a promising drug target. Interfering with capsid assembly has shown efficacy in clinical trials with small molecule capsid assembly modulators (CAMs). Herein is described the further optimization of a progressive series of diazepinone HBV CAMs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2022.128823 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!